Joel Greenblatt's MIRM Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 3,144 shares of Mirum Pharmaceuticals, Inc. (MIRM) worth $290,443, representing 0.00% of the portfolio. First purchased in 2025-Q1, this short-term holding has been held for 3 quarters.
Based on 13F filings, Joel Greenblatt has maintained this position in MIRM for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 3,144 shares. Largest reduction occurred in Q2 2025, reducing 6,043 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Mirum Pharmaceuticals (MIRM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Mirum Pharmaceuticals (MIRM) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +3,144 | New Buy | 3,144 | $92.38 |
| Q2 2025 | -6,043 | Sold Out | 0 | $0.00 |
| Q1 2025 | +6,043 | New Buy | 6,043 | $45.05 |
Joel Greenblatt's Mirum Pharmaceuticals Investment FAQs
Joel Greenblatt first purchased Mirum Pharmaceuticals, Inc. (MIRM) in Q1 2025, acquiring 6,043 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Mirum Pharmaceuticals, Inc. (MIRM) for 3 quarters since Q1 2025.
Joel Greenblatt's largest addition to Mirum Pharmaceuticals, Inc. (MIRM) was in Q1 2025, adding 6,043 shares worth $272,237.
According to the latest 13F filing for Q1 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 3,144 shares of Mirum Pharmaceuticals, Inc. (MIRM), valued at approximately $290,443.
As of the Q1 2026 filing, Mirum Pharmaceuticals, Inc. (MIRM) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Mirum Pharmaceuticals, Inc. (MIRM) was 6,043 shares, as reported at the end of Q1 2025.